Oak Family Advisors LLC decreased its position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 67.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,621 shares of the medical research company's stock after selling 3,328 shares during the quarter. Oak Family Advisors LLC's holdings in Agilent Technologies were worth $218,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA boosted its stake in Agilent Technologies by 3.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company's stock worth $2,314,784,000 after acquiring an additional 525,214 shares during the last quarter. State Street Corp boosted its position in shares of Agilent Technologies by 1.2% during the third quarter. State Street Corp now owns 12,819,897 shares of the medical research company's stock worth $1,903,498,000 after purchasing an additional 158,175 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Agilent Technologies by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 6,948,679 shares of the medical research company's stock valued at $1,028,241,000 after buying an additional 30,610 shares during the period. Nordea Investment Management AB increased its position in shares of Agilent Technologies by 2.6% in the 4th quarter. Nordea Investment Management AB now owns 3,198,715 shares of the medical research company's stock valued at $431,603,000 after buying an additional 80,819 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in Agilent Technologies by 6.6% during the 3rd quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company's stock worth $442,011,000 after buying an additional 183,716 shares during the period.
Agilent Technologies Stock Down 0.2 %
A stock traded down $0.33 during mid-day trading on Thursday, reaching $147.66. The company had a trading volume of 1,142,978 shares, compared to its average volume of 1,693,337. The company has a market capitalization of $42.17 billion, a price-to-earnings ratio of 33.41, a PEG ratio of 4.10 and a beta of 1.07. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. Agilent Technologies, Inc. has a 52 week low of $124.16 and a 52 week high of $155.35. The stock has a 50 day simple moving average of $141.25 and a two-hundred day simple moving average of $139.13.
Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The company's quarterly revenue was up .8% on a year-over-year basis. During the same quarter last year, the firm posted $1.38 EPS. As a group, equities analysts predict that Agilent Technologies, Inc. will post 5.56 earnings per share for the current fiscal year.
Agilent Technologies Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st were issued a $0.248 dividend. This is an increase from Agilent Technologies's previous quarterly dividend of $0.24. This represents a $0.99 annualized dividend and a dividend yield of 0.67%. The ex-dividend date of this dividend was Tuesday, December 31st. Agilent Technologies's payout ratio is currently 22.40%.
Insider Activity
In other news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the company. StockNews.com upgraded Agilent Technologies from a "hold" rating to a "buy" rating in a report on Tuesday, December 24th. JPMorgan Chase & Co. reduced their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating for the company in a report on Tuesday, November 26th. Citigroup raised their price objective on shares of Agilent Technologies to $165.00 and gave the stock a "buy" rating in a report on Thursday, December 19th. Bank of America reduced their target price on shares of Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. Finally, Barclays lowered their target price on Agilent Technologies from $145.00 to $135.00 and set an "underweight" rating for the company in a report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $143.62.
Get Our Latest Stock Analysis on Agilent Technologies
About Agilent Technologies
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Featured Articles
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
